Akero Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.21 billion
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Akero Therapeutics Inc had its IPO on 2019-06-20 under the ticker symbol AKRO.
The company operates in the Healthcare sector and Biotechnology industry. Akero Therapeutics Inc has a staff strength of 34 employees.
Shares of Akero Therapeutics Inc opened at $48.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $48.86 - $51.01, and closed at $49.91.
This is a +1.09% increase from the previous day's closing price.
A total volume of 696,474 shares were traded at the close of the day’s session.
In the last one week, shares of Akero Therapeutics Inc have increased by +0.34%.
Akero Therapeutics Inc's Key Ratios
Akero Therapeutics Inc has a market cap of $2.21 billion, indicating a price to book ratio of 6.0267 and a price to sales ratio of 0.
In the last 12-months Akero Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-122131000. The EBITDA ratio measures Akero Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Akero Therapeutics Inc’s operating margin was 0% while its return on assets stood at -25.33% with a return of equity of -44.79%.
In Q3, Akero Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Akero Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Akero Therapeutics Inc’s profitability.
Akero Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -14.0982. Its price to sales ratio in the trailing 12-months stood at 0.
Akero Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $379.41 million
- Total Liabilities
- $25.24 million
- Operating Cash Flow
- $3.00 million
- Capital Expenditure
- Dividend Payout Ratio
Akero Therapeutics Inc ended 2023 with $379.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $379.41 million while shareholder equity stood at $343.51 million.
Akero Therapeutics Inc ended 2023 with $70000.00 in deferred long-term liabilities, $25.24 million in other current liabilities, 5000.00 in common stock, $-399278000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $374.00 million and cash and short-term investments were $374.00 million. The company’s total short-term debt was $303,000 while long-term debt stood at $9.45 million.
Akero Therapeutics Inc’s total current assets stands at $377.95 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $6.01 million and inventory worth $0.
In 2023, Akero Therapeutics Inc's operating cash flow was $3.00 million while its capital expenditure stood at $0.
Comparatively, Akero Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Akero Therapeutics Inc stock is currently trading at $49.91 per share. It touched a 52-week high of $54.88 and a 52-week low of $54.88. Analysts tracking the stock have a 12-month average target price of $56.17.
Its 50-day moving average was $45.94 and 200-day moving average was $45.45 The short ratio stood at 7.83 indicating a short percent outstanding of 0%.
Around 825.8% of the company’s stock are held by insiders while 10561.4% are held by institutions.
Frequently Asked Questions About Akero Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company’s lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.